WC
ENTA icon

Wexford Capital’s Enanta Pharmaceuticals ENTA Stock Holding History

Wexford Capital’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-31,870
Closed -$1.26M – 71
2014
Q3 		$1.26M Buy
+31,870
New +$1.27M 0.12% 75

Other funds holding ENTA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Wexford Capital's ENTA Position: Q4 2014 in Review

Wexford Capital sold out of Enanta Pharmaceuticals (ENTA) in Q4 2014, closing a stake of 31,870 shares — an estimated $1.26M sold.

Wexford Capital first reported a position in ENTA in Q3 2014 and held it in 1 quarter. The position peaked at $1.26M in Q3 2014. 124 funds tracked by Wall St. Rank hold ENTA as of Q4 2014.

  • Wexford Capital reported no remaining Enanta Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Wexford Capital sold 31,870 Enanta Pharmaceuticals shares in Q4 2014, an estimated $1.26M.
  • Wexford Capital first reported a position in Enanta Pharmaceuticals in Q3 2014 and held it in 1 quarter.
  • Wexford Capital's Enanta Pharmaceuticals position peaked at $1.26M in Q3 2014.
  • 124 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2014.

Based on Wexford Capital's 13F filing for Q4 2014, filed 13 Feb 2015.